We are partners in research networks and consortia granted by the Spanish and EU funding programmes in diverse areas of drug discovery and applied biotechnology.
We develop active collaborations with national and international organizations including academia, research institutes and private companies.
We are corporate members of national & international scientific societies and biotech sector associations.
TOPCAPI - Thoroughly Optimised Production Chassis for Advanced Pharmaceutical Ingredients
Funded by: EUROPEAN COMMISSION - Horizon 2020 - NMBP-BIO-2016 - Proposal 720793-2 - Duration (months): 48
TOPCAPI will exploit the natural biosynthetic potential of actinomycetes as microbial cell factories to produce advanced pharmaceutical ingredients: a new anti-acne drug, in Phase II clinical trials, and three related drugs against multidrug resistant bacteria MRSA, in Phase III clinical trials. For that purpose, two common microbial bacteria will be characterized using systems biology approaches, applying integrated data analysis to transcriptomics and metabolomics experiments, combined with predictive mathematical modelling to drive the rapid improvement of these microbial cell factories for industrial production of these drugs. At the same time, we will establish a toolbox for future engineering high value advanced pharmaceutical ingredients.
MARPIPE - Improving the flow in the pipeline of the next generation of marine biodiscovery scientists
Funded by: European Commission Horizon 2020 - MSCA-ITN-ETN, Ref: 721421; Duration: 48 months
MarPipe is a consortium of 11 partners (IBP-CNR, SZN, UiT, UNIABDN, GEOMAR, KULeuven, UCC, eCOAST, MEDINA, MicroDish, Italbiotec) based in 8 countries (I, N, UK, D, B, IRL, E, NL), including 3 from the non-academic sector. MarPipe aims at further development of antimicrobial and anticancer lead compounds originating from a previous EU project (PharmaSea), and will also explore the bioactivity of deep-sea samples (5000m) collected during the recent Eurofleet-2 project in the sub-Antarctic.
OCEAN MEDICINES - Stimulating innovation by means of cross-fertilisation of knowledge
Funded by: European Commission H2020-EU.1.3.3. - Project reference: 690944 - Duration: 01/12/ 2015 to 30/11/2019
Ocean Medicines, a network of academic, research centres and SMEs across Europe, aims to establish a network of collaboration and knowledge-exchange between industrial and academic partners to further develop lead compounds from marine microorganisms having anticancer or anti-infective effects that have already been identified by the consortium.
Determination of metabolomics profiles for the diagnostic of breast cancer
BLUE AND GREEN - Marine Biotechnology
Funding: European Union’s Horizon 2020 research and innovation programme under grant agreement No 692419.
BLUEandGREEN aims to increase the performance of CIIMAR in the area of Marine Biotechnology, and joins CIIMAR with four internationally-leading counterparts at the EU level: the University of Helsinki - Finland, the University of Bergen - Norway, GEOMAR, Helmholtz Centre for Ocean Research Kiel – Germany, and Fundación MEDINA - Spain.
ENABLE - European Gram Negative Antibacterial Engine
Funded by: Innovative Medicines Iniciative (IMI)- New Drugs for Bad Bugs ND4BB Duration: 2013-2018
MICROSMETICS - Exploitation of microbial biodiversity for the discovery and development of novel cosmeceutical agents
Funded by: European Union FP7-PEOPLE-2013-IAPP under grant agreemet nº 612276 Duration: 2013-2017
Impacto en salud pública de la dispersión de enterobacterias productoras de carbapenemasas en España: Caracterización molecular de las cepas circulantes
Funded by: under agreement nº PI12/0242 Duration: 2013-2015
PharmaSea - Value Flow in the Marine Biodiscovery Pipeline
Funded by: European Union FP7-KBBE-2012-6-singlestage under grant agreemet nº 312184 Duration: 2012-2015
ParaMet - An analysis of parasite metabolism-from metabolism to intervention
Funded by: European Union FP7-PEOPLE-2011-ITN under grant agreemet nº 290080 - 2012-2015
COCULMICRO - Cocultivation of microorganisms as a strategy for discovery of new natural products with antimicrobial properties
DOSYMNPS - Novel applications of diffusion NMR spectroscopy in microbial natural products research
Funded by: European Union FP7-PEOPLE-2011-CIG Marie Curie Support for Training & Career develoment of researchers under grant agreement nº PCIG09-GA-2011-293762 - 09/2011-08/2015
Descubrimiento de nuevos antibicoticos mediante la combinación de dos estrategias: cultivo de bacterias no cultivadas previamente y muestreo de hábitats salinos de Andalucía
Funded by: Regional Government of Andalucía. Project in Scientific Excellence under grant agreement nº CTS-5859 - 2011-2013
Descubrimiento y desarrollo de nuevos antibióticos frente a bacterias gram negativas multiresistentes y de fármacos potenciadores de la actividad de carpabenems
Funded by: Regional Government of Andalucía. Project in Scientific Excellence under grant agreement nº CVI-6909 - 2011-2013
Antibiotics against multiresistant Gram negative pathogens and potentiators of carbapenem activity
Funded by: Research In Health Sciences Program, Health Sciences Institute Carlos III under grant agreement nº PI10/00745 - 2011-2013
Use of zebrafish as experimental model: evaluation of mithocondrial disfunction and identification of neuroprotective compounds from microbial natural in collaboration with The University of Granada
Funded by: Regional Government of Andalucía. Project in Scientific Excellence under grant agreement nº CTS-5784
Equipamiento complementario de alto rendimiento para el aislamiento y caracterización de Productos Naturales Bioactivos
Funded by: Spanish Ministry of Science and Innovation under grant agreement INP-2011-0016-PCT-010000-ACT6 - 2011
Discovery and characterization of new antibiotics by culturing previously uncultured bacteria
Funded by: Spanish Ministry of Science and Innovation. Non-Oriented Basic Research Project under grant agreement nº SAF2010-15010 - 2011-2013
Búsqueda de Nuevos Antibacterianos y Caractericación de la Librería de Productos Naturales de la Fundación MEDINA
Funded by: Ministerio de Ciencia e Innovación dentro de los Presupuestos Generales del Estado para el 2010 aplicación presupuestaria 21.03.463B.789.01 - 2010
Discovery and development of pharmaceuticals efficacious for amyotrophic lateral sclerosis (Lou Gerhig´s Disease)
Funded by: Ministry of Science and Innovation under grant agreement: PPT-300000-2009-2011
AntiFun: The cell wall as a target to improve antifungal therapy against Aspergillosis
Funded by: ERA-NET: Pathogenomics (7th FP) - 2009-201